|12.38 0.84 (7.28%)||12-01 16:00|
|Targets||6-month :||15.44||1-year :||18.03|
|Resists||First :||13.22||Second :||15.44|
|Supports||First :||9.98||Second :||7.98|
|MAs||MA(5) :||11.06||MA(20) :||10|
|MA(100) :||12.09||MA(250) :||9.76|
|MACD||MACD :||0.2||Signal :||-0.2|
|%K %D||K(14,3) :||83.1||D(3) :||78.6|
|52-week||High :||16.86||Low :||0.37|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AMAM ] has closed above the upper band by 8.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 18.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||13.24 - 13.31||13.31 - 13.36|
|Low:||11.02 - 11.09||11.09 - 11.14|
|Close:||11.42 - 11.54||11.54 - 11.65|
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
Wed, 22 Nov 2023
Billionaire Seth Klarman's Biotech Stock Picks - Yahoo Finance
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||63 (M)|
|Held by Insiders||5.897e+007 (%)|
|Held by Institutions||0 (%)|
|Shares Short||0 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-48 %|
|Return on Assets (ttm)||350.9 %|
|Return on Equity (ttm)||-18.7 %|
|Qtrly Rev. Growth||4.09e+006 %|
|Gross Profit (p.s.)||0.11|
|Sales Per Share||0.09|
|Qtrly Earnings Growth||0.4 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-58 (M)|
|Price to Book value||0|
|Price to Sales||136.11|
|Price to Cash Flow||0|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|